Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation

View ORCID ProfileHossein Gorji, View ORCID ProfileMarkus Arnoldini, View ORCID ProfileDavid F. Jenny, View ORCID ProfileWolf-Dietrich Hardt, View ORCID ProfilePatrick Jenny
doi: https://doi.org/10.1101/2020.11.30.20239566
Hossein Gorji
1École Polytechnique Fédérale de Lausanne, MCSS, CH-1015 Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hossein Gorji
Markus Arnoldini
2Department of Health Sciences and Technology, ETH Zürich, CH-8093 Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Markus Arnoldini
David F. Jenny
3Department of Mathematics, ETH Zürich, CH-8092 Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David F. Jenny
Wolf-Dietrich Hardt
4Institute of Microbiology, D-BIOL, ETH Zürich, CH-8093 Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wolf-Dietrich Hardt
  • For correspondence: hardt@micro.biol.ethz.ch jenny@ifd.mavt.ethz.ch
Patrick Jenny
5Institute of Fluid Dynamics, D-MAVT, ETH Zürich, IFD, CH-8092 Zürich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Patrick Jenny
  • For correspondence: hardt@micro.biol.ethz.ch jenny@ifd.mavt.ethz.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Covid-19 mitigation commonly involves contact tracing (CT) and social distancing. Due to its high economic toll and its impact on personal freedom, we need to ease social distancing and deploy alternative measures, while preventing further waves of infections. While reliable mass testing (for virus RNA) would require too many resources to be effective, CT, which focuses on isolating symptomatic cases and their contacts, has been implemented in many countries. However, the latter approach has reduced efficiency when high numbers of positive patients are burdening the tracing centers. Moreover, CT misses transmissions by asymptomatic cases. Therefore, its effect in reducing the reproduction number has a theoretical limit.

To improve effectiveness of contact tracing, we propose to complement it with a strategy relying on identifying and testing symptom free subgroups with a significantly higher than average virus prevalence. We call this smart testing (ST). By testing everybody in these subgroups, in addition to symptomatic cases, also large fractions of pre- and asymptomatic persons can be identified, which enhances the effectiveness of contact tracing. High prevalence subgroups can be found in different ways, which are discussed in this paper. A particularly efficient way is via preselection using cheap and fast virus antigen tests, as proposed recently. Mathematical modeling quantifies the potential reduction of the reproduction number by such a two-stage ST strategy. In addition to global scenarios, also more realistic local applications of two-stage ST have been investigated, that is, within counties, institutions, schools, companies, etc., where members have internal as well as external contacts. All involved model parameters have been varied within realistic ranges and results are presented with probabilities. Even with the most pessimistic parameter set, these results suggest that the effect of two-stage ST on the reproduction number would clearly outweigh its economic cost. Two-stage ST is technically and logistically feasible. Further, it is locally effective also when only applied within small local subpopulations. Thereby, two-stage ST efficiently complements the portfolio of mitigation strategies, which allow easing social distancing without compromising public health.

Single Sentence Summary Identification of high prevalence groups within subpopulations to enhance detection rate of Covid-19 infections by virus RNA tests combined with subsequent isolation.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

HG acknowledges funding from the Swiss National Science foundation (grant number 174060).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Since this is a purely theoretical study, no ethics approval was necessary.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data is included in the manuscript and supporting information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation
Hossein Gorji, Markus Arnoldini, David F. Jenny, Wolf-Dietrich Hardt, Patrick Jenny
medRxiv 2020.11.30.20239566; doi: https://doi.org/10.1101/2020.11.30.20239566
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Smart Investment of Virus RNA Testing Resources to Enhance Covid-19 Mitigation
Hossein Gorji, Markus Arnoldini, David F. Jenny, Wolf-Dietrich Hardt, Patrick Jenny
medRxiv 2020.11.30.20239566; doi: https://doi.org/10.1101/2020.11.30.20239566

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2464)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4843)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)